Accuray tomotherapy® helical radiotherapy system helps preserve breast cancer patients' long-term heart and lung functionality

Sunnyvale, calif., feb. 10, 2022 /prnewswire/ -- accuray incorporated (nasdaq: aray) announced today that data from a phase iii, randomized controlled trial, tomobreast, indicate post-surgery hypofractionated radiotherapy delivered with the tomotherapy® system is superior to conventional radiotherapy in preserving long-term heart and lung functioning in women with early breast cancer.
ARAY Ratings Summary
ARAY Quant Ranking